Elan shares down 50% after Tysabri revelation

Shares in Athlone-based pharmaceutical firm Elan have fallen in value by more than 50% on the Irish stock exchange this morning.

The drop comes after the company discovered a third case of PML in a patient treated with its multiple sclerosis drug Tysabri.